Download image:

Bradford B. Walters

Vice President and Chief Medical Officer

Brad Walters, MD, PhD, MBA, is a vice president and the chief medical officer of RTI International. After completing his PhD, MD, a surgical internship, and a neurosurgical residency, he joined the faculty of the University of North Carolina at Chapel Hill School of Medicine, where he assisted in establishing the radiosurgery program and the epilepsy surgery program. His research focused on central nervous system trauma. After completing his MBA, he joined Academy Funds serving as principal and then partner, and on the boards of directors of Kucera Pharmaceutical Company, ParinGenix, and Curry Pharmaceuticals. He was then appointed a member of the Building Entrepreneurial Companies Work Group of the North Carolina Biotechnology Center Strategic Plan, and to the Governor's Task Force on Nanotechnology and North Carolina's Economy. From 1999 through 2006, he served as a member of the board of directors of NCHICA.

At RTI, a primary responsibility of Dr. Walters’s has been to help shepherd internal drug candidates into clinical trials. Over his career, he has helped bring three new chemical entities through the Investigational New Drug process of the FDA into five Phase 1 trials. He also serves as Chairman of the Infectious Disease Advisory Group; as a member of the Board of Directors and Executive Committee of the RTI Press; as a member of the RTI Risk Management Committee and the Health, Environment, Risk, Safety, and Security Committee; as a member of the Commercialization Team; as RTI’s representative on the North Carolina Board of Science, Technology, and Innovation; as the RTI Research Integrity Officer; and as an internal consultant to projects across the Institute.  


PhD, Anatomy and Embryology, University of London; MD (cum laude), Harvard Medical School/Massachusetts Institute of Technology Division of Health Sciences and Technology; MBA, Kenan-Flagler Business School, University of North Carolina at Chapel Hill; AB, Chemistry and Physics (summa cum laude), Harvard College.

Latest Publications

Buda, J.J., Carroll, F.I., Kosten, T.R., Swearingen, D., & Walters, B.B. (2015). A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic. Neuropsychopharmacology, Advance Online Publication .
Marsden Jr., W.E., Fedenisn, A., Greer, J.A., Herstein, J., Powers, M.K., Sampson, J.M., Sax, E.W., Vosburgh, K., Walsh, K.F., Walters, B.B., et al. (December 2014). Ebola as an organizational policy challenge: A brief primer: RTI Press Publication No. PB-0006-1412. Research Triangle Park, NC: RTI Press.
Walters, B.B. (2014). Neurological adverse events. In Andrews, E.B. & Moore, N. (Eds.), Mann's Pharmacovigilance (3rd ed.) (pp. 585-610). Chichester, UK: Wiley-Blackwell.
Rao, N.V., Argyle, B., Xu, X.Y., Reynolds, P.R., Walenga, J.M., Prechel, M., Prestwich, G.D., MacArthur, R.B., Walters, B.B., et al. (2010). Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. American Journal of Physiology. Cell Physiology, 299 (1):C97-C110.
Thompson, J.E., Castillo, M., Kwock, L., & Walters, B. (1998). Usefulness of proton MR spectroscopy in the evaluation of temporal lobe epilepsy. American Journal of Roentgenology (AJR), 170 (3):771-776.
View all publications by Bradford B. Walters (12)


  • Preclinical and Clinical Development
  • Neurological Surgery